Tandem Diabetes Care (TNDM) said Tuesday that the US Food and Drug Administration has cleared its Control-IQ+ automated insulin delivery algorithm for use in adults with type 2 diabetes.

The technology is expected to be available in the US in March, Tandem said.

The approval was based on a clinical trial involving more than 300 participants with type 2 diabetes, comparing the use of Tandem's t:slim X2 pump with Control-IQ+ to multiple daily insulin injections, the company said.

The full trial results will be presented at a diabetes conference in March, Tandem added.

Tandem shares were more than 5% higher in recent trading.

Price: 34.30, Change: +1.64, Percent Change: +5.01